Table 1 Overview of published US pancreatitis consortia studies since 2015
From: The emerging landscape of biorepositories among pancreatitis consortia studies in the US
Study | Objectives | Related diseases | Main inclusion/exclusion criteria | # of patients enrolled | Centers | Federal funding | Start time | Study completion | References |
|---|---|---|---|---|---|---|---|---|---|
SVI | pancreatic stent placement (PSP) vs indomethacin for preventing post-ERCP pancreatitis (PEP) | PEP | included: adults at high risk for PEP who were planned to undergo PSP excluded: patients who either have an allergy to NSAIDS or recently took them, recent AP attack | 837 | 20 (US, Canada) | NIDDK | 2015 | completed | |
PROCEED | characterize the progression of pancreatitis to CP | AP, ARP, CP | included: adults at different stages of pancreatitis; non-diseased controls | not final | 10 (US) | NCI and NIDDK | 2017 | ongoing | |
INSPPIRE 2 | characterize children with ARP or CP, find predictors for early onset CP and sequelae | pediatric-focused ARP, CP | included: children (<18 years of age) with ARP or CP | 720 | 22 (US, Canada, Israel, Australia) | NCI and NIDDK | 2017 | ongoing | Uc et al.7 |
POST | determine which patients with ARP or CP should undergo TPIAT | ARP, CP, diabetes | included: adults and children undergoing TPIAT | 375 | 12 (US) | NIDDK | 2017 | completed | Bellin et al.8 |
SHARP | efficacy of minor papilla endoscopic sphincterotomy (miES) for ARP patients with pancreas divisum | ARP, pancreas divisum | included: adults with ARP and pancreas divisum who have no other obvious structural etiology for ARP, at least 1 AP attack within 24 months of enrollment | 181 | 22 (US, Canada) | NIDDK | 2018 | completed | Coté et al.9 |
ACCESS-AP | impact of short-term changes in drinking on triggering AP | AP, ARP | included: adults with alcohol overuse admitted with an AP attack | 145 | 5 (US) | DOD | 2020 | completed | Jeon et al.10 |
DREAM | characterize diabetes onset following AP | AP, ARP, diabetes | included: adults who developed AP within 90 days of enrollment excluded: patients with definite CP, history of pancreatic necrosectomy, tumors, or surgery, concomitant diabetogenic medication, known pregnancy, severe systemic illnesses | 800 (not final) | 10 (US) | NIDDK | 2022 | ongoing |
